不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
泰国鼻型结外 NK/T 细胞淋巴瘤患者以 L-天冬酰胺酶为基础方案作为一线化疗方案的治疗结局：5 年回顾性研究
英文原题：A five-year retrospective study of treatment outcomes using the L-asparaginase-based regimen as a first-line chemotherapy protocol for patients diagnosed with extranodal NK/T-cell lymphoma, nasal-type, in Thailand.
查看英文原题
A five-year retrospective study of treatment outcomes using the L-asparaginase-based regimen as a first-line chemotherapy protocol for patients diagnosed with extranodal NK/T-cell lymphoma, nasal-type, in Thailand.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
以 L-天冬酰胺酶为基础的治疗方案显示出与其他研究结果相似的结果。
中文摘要
目的
评估新诊断鼻型结外 NK/T 细胞淋巴瘤（ENKTL）患者接受含 L-天冬酰胺酶化疗作为一线治疗后的临床结局。
材料与方法
回顾性分析泰国诗里叻医院 2012—2016 年新诊断 ENKTL 患者的资料。
结果
27 例患者中男性 16 例、女性 11 例，中位年龄 52 岁（范围 25–83 岁）。原发部位为鼻腔及鼻部区域 23 例、皮肤 4 例。I、II、III、IV 期分别为 10、8、1、8 例。按 NK 细胞淋巴瘤预后指数 PINK 和 PINK-E 分层，低、中、高危患者分别为 14、8、5 例和 11、4、4 例。化疗方案为 SMILE（24 例）和 AspaMetDex（3 例）；14 例化疗后接受局部放疗。26 例可评估患者的总缓解率为 69%，其中 14 例（52%）完全缓解。中位无进展生存期和总生存期分别为 32 个月和 33 个月。最常见的 L-天冬酰胺酶方案相关并发症为低纤维蛋白原血症（24 例）和超敏反应（9 例）。随访时总死亡人数为 14/27（52%），死因为脓毒症（11 例）和疾病进展（3 例）。讨论：含 L-天冬酰胺酶方案的结果与其他研究相近，包括采用造血干细胞移植的研究；这提示在移植费用难以承担时或可避免移植。治疗期间应密切监测方案相关的血栓或出血。
结论
含 L-天冬酰胺酶方案作为 ENKTL 一线治疗可取得良好结局。
展开英文摘要原文
OBJECTIVE
To assess clinical outcomes of newly diagnosed extranodal NK/T-cell lymphoma nasal-type (ENKTL) patients treated with L-asparaginase-containing chemotherapy as first-line chemotherapy.
MATERIALS AND METHODS
We retrospectively reviewed data of new ENKTL patients in Siriraj Hospital, Thailand during 2012-2016.
RESULTS
Among 27 patients, 16 were men and 11 were women, and their median age was 52 (range, 25-83) years. The primary sites were the aero-nasal area (23) and skin (4). Clinical stages of ENKTL were I, II, III and IV in 10, 8, 1 and 8 patients, respectively. Patients classified according to the NK cell-lymphoma prognostic index with PINK (27) and PINK-E (19) as low, intermediate, and high were 14, 8, 5, respectively and 11, 4, and 4, respectively. Chemotherapy regimens used were SMILE (24) and AspaMetDex (3). Fourteen patients received post- chemotherapy local radiation. The overall response rate for 26 assessable patients was 69%, with complete response in 14 patients (52%). Median progression-free and overall survival were 32 and 33 months, respectively. The most common L-asparaginase regimen related complications were hypofibrinogenemia (24) and hypersensitivity (9). The overall mortality at follow-up was 14/27 (52%) owing to sepsis (11) and disease progression (3). DISCUSSION: L-asparaginase-based regimens showed similar results as other study results. including those in which hematopoietic stem cell transplantation was performed, suggesting that transplantation can be avoided if it is unaffordable. Thrombosis or bleeding, the regimen side effects, should be carefully monitored during treatment.
CONCLUSIONS
L-asparaginase-based regimens offer a good outcome as a front-line treatment for ENKTL.
论文信息
- 作者
- Vittayawacharin P、Khuhapinant A
- 单位
- Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.Thailand
- 期刊
- Hematology (Amsterdam, Netherlands)2021 Dec
- 原文标识
- PubMed 33427594 · DOI 10.1080/16078454.2020.1867783